Cancer Clinical Investigator Team Leadership Award for Fiscal Year (FY) 2018

Department of Health and Human Services

Participating Organizations
National Cancer Institute (NCI) (http://www.nci.nih.gov)

Title: Cancer Clinical Investigator Team Leadership Award (CCITLA)

This is a reissue of the FY 2017 administrative supplement award announcement. Please note the following modifications in the current announcement:

- Cancer Centers which will enter an extension year during FY 2018 are not eligible to submit an application for this announcement since new administrative supplements cannot be paid to grants in an extension year.
- Candidates who are physicians (e.g., M.D., D.O.), must be board certified or have equivalent training and qualifications in specialty area, e.g., medical oncology, radiation oncology, oncology nursing, surgical oncology, gynecologic oncology or equivalent.
- Current or past Principal Investigators of peer-reviewed research grants of at least $125,000 in direct costs per year for a minimum of 3 years from any of the organizations listed in the Organizations with Peer Review Funding Systems at: https://cancercenters.cancer.gov/PoliciesResources/PoliciesResources are not eligible to be nominated.
- In the letter of intent, the name of the candidate and individuals providing letters of recommendation can be included, but are not required.
- A Tips for Applicants section has been added to page 5 of the announcement.

Key Dates

Letter of Intent Due Date: October 27, 2017

Application Due Date: by 5:00 PM local time of applicant organization on November 27, 2017

Earliest Start Date: March 2018 for Cancer Centers with P30 Cancer Center Support Grants (CCSGs) with start dates of December through March. For Cancer Centers with P30 CCSGs with start dates of April through September, the anticipated start date is the 2018 start date of the parent P30 CCSG.

Award Information

The Cancer Clinical Investigator Team Leadership Award (CCITLA) is an administrative supplement award which recognizes and supports outstanding clinical investigators with records of developing and promoting a culture of successful clinical research. It is the
intent of the CCITLA to support mid-level clinical investigators at NCI-designated Cancer Centers who are participating extensively in NCI-funded clinical trials and clinical research efforts. The award is also intended to retain clinical investigators in academic clinical research careers. A candidate for the CCITLA must be nominated by the Cancer Center Director.

The Recalcitrant Cancer Research Act of 2012, P.L. 112-239 (S. Amdt. 3180 to S. 3254/H.R. 4310, 112th Congress) (RCRA) calls upon the NCI to "develop scientific frameworks that will help provide the strategic direction and guidance needed to make true progress against recalcitrant or deadly cancers." Recalcitrant cancers are defined as those cancers with a five-year relative survival rate below 50 percent. In response, the NCI developed scientific frameworks to enhance the study of pancreatic ductal adenocarcinoma (PDAC) and small cell lung cancer (SCLC) (http://www.cancer.gov/about-nci/legislative/recent-public-laws).

Consistent with the NCI’s interest in recalcitrant cancers, applications with candidates whose clinical research focuses on PDAC or SCLC are encouraged, but not required.

Funds Available and Allowable Costs

The NCI intends to provide partial salary support for clinical investigators at up to 10 NCI-designated Cancer Centers through administrative supplements to P30 CCSGs. The total supplemental budget should not exceed $60,000 (total costs) per year for a total of two years, including salary, fringe benefits and associated facilities and administrative costs.

The candidate must devote at least 15% (1.8 calendar months) effort to the activities associated with this award and the sponsoring institution must protect the awardee’s time for these activities. Although cost sharing is not required, institutions are encouraged to cost share if needed to attain greater than 15% effort for the candidate.

All awards are subject to the terms and conditions of the CCSG notice of grant award and cost principles and other considerations described in the NIH Grants Policy Statement (http://grants.nih.gov/grants/policy/nihgps/index.htm).

Support provided under this supplemental award is not transferable to another investigator or institution.

Allowable costs are limited to:
- Salary (for candidate only), fringe benefits, and associated facilities and administrative costs.
- Travel (up to $2500/year) and registration fees (up to $2500/year) (for candidate only) to attend courses, seminars, meetings, conferences and workshops that support the intent of this award. In the budget justification, include the destination, dates or duration of stay for all anticipated travel. It is important to clearly state how the travel directly relates to the intent of this award.
Funds from this award may not be used for:

- Research-related costs, including but not limited to research supplies, computers, equipment, core facility fees, or sample or data analysis,
- Salary for personnel other than the candidate,
- Secretarial or administrative assistance and supplies.

Questions about allowable costs should be directed to the NCI Coordinating Center for Clinical Trials (CCCT) CCITLA Program Director, Dr. Jennifer Hayes (hayesjf@mail.nih.gov).

Eligibility Criteria for Institutions and Candidates

- Only NCI-designated Cancer Centers participating in NCI-funded clinical trials are eligible to apply for this supplement.
- Cancer Centers which received the first payment of a two-year CCITLA supplement in 2017 (2017 CCITLA Award Recipients) are not eligible to submit an application for this announcement.
- Cancer Centers which will enter an extension year during FY 2018 are not eligible to submit an application for this announcement since new administrative supplements cannot be paid to grants in an extension year.

Questions about eligibility should be directed to the NCI CCCT CCITLA Program Director, Dr. Jennifer Hayes (hayesjf@mail.nih.gov). Only individuals who have never received this award may be nominated. For a list of past awardees, please refer to: https://www.cancer.gov/about-nci/organization/ccct/funding/ccitla/2017AwardeeList

Nomination: The candidate must be nominated by the Cancer Center Director (Principal Investigator (PI) of the P30 CCSG) based on the candidate’s qualifications, involvement in NCI-funded clinical trials, interests, accomplishments, motivation, ability to promote a successful clinical research culture and plan to pursue an academic career in clinical research.

Number of Applications

Each eligible NCI-designated Cancer Center may submit only one application.

Eligibility Criteria for the Clinical Investigator

All criteria must be met at the time of the application submission deadline (November 27, 2017) to be considered for the award.

- The candidate must be one of the following:
  - Physician (e.g., M.D., D.O.), board certified or have equivalent training and qualifications in specialty area, e.g., medical oncology, radiation oncology, oncology nursing, surgical oncology, gynecologic oncology or equivalent.
  - Oncology nurse, clinical psychologist or similarly qualified clinician with a doctoral degree.
• Currently practicing in the oncology clinical setting.

• Practicing at least 3 years but no more than 8 years from initial post-oncology fellowship academic appointment as of application submission deadline (November 27, 2017).

• Full-time faculty member (academic or clinical track) at the assistant or associate professor level, eligible for promotion/tenure or with permanent status (if such activities are generally available to individuals at the applicant institution). A full professor, or anyone above the associate professor level, regardless of tenure status, is not eligible to be nominated.

• Engaged in the conduct of NCI-funded cancer clinical trials at an academic medical center.

• Potential for leadership of the Cancer Center’s clinical trials. For example, setting clinical research priorities; overseeing clinical trials; submitting protocols to the Institutional Review Board (IRB); monitoring adverse event reporting; and increasing enrollment in NCI-funded cancer clinical trials.

• U.S. citizen or noncitizen national of the United States possessing a United States passport that delineates and certifies status as a national but not a citizen of the United States, or have been lawfully admitted for permanent residence and possess a currently valid Permanent Resident Card (USCIS Form I-551) or other legal verification of such status.

• Candidate cannot have received the CCITLA previously (applies to the candidate only, not the Cancer Center).

• Not currently or previously:
  o A Principal Investigator of a National Institutes of Health (NIH) R, K, P, U, DP, RC, RF, RL, RM, UC, UF, UH, UL, UM, UT series research grant (http://grants.nih.gov/grants/funding/ac_search_results.htm) with the exception of R03 awards, R13 awards, R15 awards, R18 awards, R25 awards, R28 awards, R34 awards, R38 awards, R90 awards, RL5 awards, RL9 awards, career development awards or mentored awards where the PI is required to be mentored by another investigator.
  o Individuals who are currently supported by NIH Mentored Career Development (K) Awards are eligible to be nominated for the CCITLA if the support period for the K grant will end by the date when the CCITLA award will be made (approximately March 2018 for Centers with annual start dates in December through March; for Centers with start dates in April – September, the CCITLA is awarded on the Center’s start date). Since the CCITLA is an administrative supplement and not a research grant, it cannot replace effort on a K award.
FY 2018 Cancer Clinical Investigator Team Leadership Award (CCITLA)

• A project leader or co-leader on a NIH competing multi-component research or center grant or cooperative agreement within a P or U series grant (e.g., P01 Program Project Grant, U01 or U19 Research Program Cooperative Agreement, P50 Specialized Center Grant).
  ▪ The candidate's biographical sketch should include current, pending, and past support for any NIH P or U series grants and indicate that the candidate is NOT a project leader or co-leader of a research project within these grants.
  
• A Principal Investigator of a peer-reviewed research grant of at least $125,000 in direct costs per year for a minimum of 3 years from any of the organizations listed in the Organizations with Peer Review Funding Systems at: https://cancercenters.cancer.gov/PoliciesResources/PoliciesResources

• Recipients of ASCO Career Development Award ARE eligible and may be nominated for this award.

Tips for Applicants
• The application should clearly show that the candidate is involved in NCI-funded clinical trials.
• The application should highlight how this award would permit the candidate to expand current activities and/or develop/engage in new activities related to promoting successful clinical research. Highlight how the activities planned under the award are different than the candidate’s regular activities.
• The application should address the review criteria in the announcement.

Application Procedure:

1. Cover Letter (1-2 pages):
   A cover letter, signed by the PI of the P30 CCSG, must accompany each application and include:
   • the name of the candidate
   • statement verifying that the candidate meets the eligibility criteria of the award
   • the process used to select the candidate
   The Cancer Center Director’s letter of support should be included with the other letters of support for the application and not as part of the cover letter.

2. Body of the Application:
   The application should include (in the order listed):
   
2) A biographical sketch of the candidate. The Biographical Sketch Format Page is available at http://grants.nih.gov/grants/forms/biosketch.htm. In Section D. Research Support, list all ongoing, completed and pending research projects (Federally or non-Federally-supported), indicating if the candidate is/was a Principal Investigator/co-Principal Investigator. For any NIH P and U series grants, indicate that the candidate is/was NOT a project leader or co-leader of a research project within the grant.

3) A narrative (3-5 pages) that addresses the review criteria at the end of this document, including:
   • How the candidate’s training, experience, current activities, and planned activities under this award will support promotion of a successful clinical research culture at his/her institution.
   • The candidate’s involvement in past and present NCI-funded cancer clinical trials at academic medical centers and clinical trial-related activities.
   • How this award would permit the candidate to expand current activities and/or develop/engage in new activities related to promoting successful clinical research. Highlight how the activities planned under the award are different than the candidate’s regular activities.
   • The candidate’s plans for a career in academic clinical research.

4) An outline (no longer than 2 pages) and description of activities and projects planned under this award, including a timeline. An award can support multiple projects/activities as time, effort, and resources allow.

Examples of projects and activities considered appropriate to this award include, but are not limited to (Note: projects/activities listed below are not ordered by priority):
   • Organizing courses, lecture/seminar series, educational sessions, or workshops for clinical research staff, patient advocates, patients, and other stakeholders which contribute to building or enhancing a culture of clinical research at the awardee’s institution.
   • Attending courses, seminars, meetings, conferences, or workshops that enhance the awardee’s ability to contribute to a successful clinical research program at his/her institution.
   • Engaging fellows and new faculty in clinical research efforts at the awardee’s institution.
   • Mentoring junior staff/fellows/trainees.
   • Participating on a particular cancer center committee (e.g., Institutional Review Board (IRB)) that enhances the awardee’s clinical research knowledge or leadership.
   • Developing a clinical trial concept and/or protocol.
   • Designing and implementing initiatives to better coordinate, support and integrate a clinical trials culture at the institution.
• Developing streamlined processes for the awardee’s institution’s committees (e.g., IRB, Data Safety Monitoring Board, Protocol Review and Monitoring Committee, Scientific Review Committee).
• Resolving activation or accrual issues for a trial at the awardee’s institution.

5) A budget entered on Form Pages 4 and 5 of PHS 398 (http://grants.nih.gov/grants/funding/phs398/phs398.html) for the calendar months of effort for the Clinical Investigator during the first and second year, with appropriate justification. In the budget justification, include the destination, dates or duration of stay for all anticipated travel. It is important to clearly state how the travel is directly related to the intent of this award.


7) **Letters of Support:** Three signed letters of support on behalf of an individual’s application must be submitted with the application. The letters should be appended to the application after the PHS 398 Checklist in the PDF of the application.
   • One of the letters of support must be provided by the Cancer Center Director and should be appended to the application with the other letters of support, rather than included in the cover letter.
   • At least one of the letters of support should be an institutional support letter from the Department Chair or appropriate institutional official that indicates the institution’s level of commitment to fostering the candidate’s career as an academic clinical investigator, as reflected by the extent to which the candidate will have dedicated time for activities proposed in the application. This letter must demonstrate a commitment to allow at least 15% (1.8 calendar months) effort for activities proposed in the application. Letters should include a description of the academic status of the applicant and any additional support provided by the institution.

**Letter of Intent to Submit an Application:**

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NCI staff to estimate the potential review workload and plan the review.

Prospective Cancer Center applicants are asked to submit a letter of intent that includes the following information:

• intent to apply for this administrative supplement
• title of this funding opportunity
• name of the Cancer Center and Cancer Center Director (PI of the P30 CCSG)
• Not required, but please include if known:
  o the name and email address of the Candidate
the names and institutional affiliations of the two individuals other than the Cancer Center Director who will provide letters of support for the application.

The letter of Intent should be provided by e-mail no later than October 27, 2017 to:

Dr. Jennifer Hayes  
Program Director, Coordinating Center for Clinical Trials  
National Cancer Institute  
hayesjf@mail.nih.gov

Ms. Nga Nguyen  
Program Analyst, Office of Cancer Centers  
National Cancer Institute  
nguyenn2@mail.nih.gov

Where to Send the Cover Letter, Application, and Letters of Support

Applications are due no later than November 27, 2017.

Email an electronic copy of the application in PDF format, including the cover letter and letters of support, to both program staff listed below.

Dr. Jennifer Hayes  
Program Director, Coordinating Center for Clinical Trials  
National Cancer Institute  
hayesjf@mail.nih.gov

Ms. Nga Nguyen  
Program Analyst, Office of Cancer Centers  
National Cancer Institute  
nguyenn2@mail.nih.gov

Review Criteria There is no predetermined weighting for the categories of review criteria. Bulleted items in each category serve as examples for addressing review criteria. An application does not need to be strong in all areas to receive a meritorious assessment.

Candidate’s training and experience

- Does the candidate have formal training and experience strongly supporting a clinical team leadership role in oncology research?
• Does the candidate have leadership experiences in one or more clinical research activities (e.g., institutional or multi-center clinical trials, cancer center clinical trials office, IRB, Data Safety Monitoring Board, Protocol Review and Monitoring Committee, Scientific Review Committee, involvement in the NCI National Clinical Trials Network (NCTN) or the NCI Community Oncology Research Program (NCORP))?

• Has the candidate participated in NCI-sponsored clinical trials such as those funded through the Division of Cancer Treatment and Diagnosis (DCTD), Division of Cancer Prevention (DCP), Division of Cancer Control and Population Sciences (DCCPS), Office of the Director (OD) or Cancer Centers?

• Does the candidate currently participate in NCI-funded clinical trials?

Candidate’s current clinical research activities

• How does the candidate serve as a critical supporter and promoter of the overall clinical research mission at his or her institution?

• To what extent does the candidate mentor or guide trainees, junior investigators, as well as nursing, clinical research and other staff, and patients/patient advocates in support of clinical trial activities?

• To what extent is the candidate currently involved in clinical research activities (e.g., institutional or multi-center clinical trials, cancer center clinical trials office, IRB, Data Safety Monitoring Board, Protocol Review and Monitoring Committee, Scientific Review Committee, streamlining clinical trial processes, enhancing clinical trial enrollment, involvement in the NCTN or NCORP)?

• To what extent is the candidate currently involved in NCI-sponsored clinical trials such as those funded through the DCTD, DCP, DCCPS, OD or Cancer Centers?

• Does the candidate's involvement and influence in clinical trials research at his or her institution cross disease sites, modalities, or departments?

Candidate’s planned activities to promote a successful clinical research culture at his/her institution

• How would this award permit the candidate to expand current activities and/or develop/engage in new activities related to promoting successful clinical research that otherwise would not be possible?
• To what extent do the activities proposed in the application promote and/or enhance clinical trials and a successful clinical research culture at the candidate’s cancer center?

• To what extent do the activities proposed in the application promote retention of the candidate in an academic clinical research career?

• Does the application indicate appropriate commitment of time and effort for the proposed activities?

Institutional commitment to support the candidate’s planned activities and career in clinical research

• Is there clear commitment of the institution to relieve the candidate of sufficient duties to allow at least 15% (1.8 calendar months) effort for activities proposed in the application?

• Is the level of institutional commitment to the career development of the candidate appropriate to be considered for this award?

• Does the candidate’s institution intend to continue to provide or augment its support for the candidate to promote clinical research beyond the award performance period?

Reporting Requirements: A progress report for the CCITLA supplement must be included as a separately labeled section in the annual progress report for the Cancer Center grant for any reporting period for which CCITLA supplemental funds are received.

The progress report should include:
• Details on the progress and outcome of activities and projects listed in the application.
• Awards and honors received during the performance period related to activities under this award.
• Publications, journal articles, and patents related to this award.
• Impact to date of the award on the candidate’s career development.
• Opportunities that otherwise would not have been possible without the award.
• Value added by the award (e.g., for the institution or other staff).

Publications resulting from this award should acknowledge the funding source as follows: “This study was supported in whole or in part by funding from the Cancer Clinical Investigator Team Leadership Award awarded by the National Cancer Institute Coordinating Center for Clinical Trials (CCCT) though a supplement to P30 xxxxxxx.”
Publications, journal articles, and/or patents produced under an NIH award-supported project must bear an acknowledgment and disclaimer, as appropriate, as provided in NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards Section 8.2 “Administrative Requirements—Availability of Research Results: Publications, Intellectual Property Rights, and Sharing Research Resources.”

**NCI Contacts**
For programmatic questions concerning this supplement, contact Dr. Jennifer Hayes in the Coordinating Center for Clinical Trials ([hayesjf@mail.nih.gov](mailto:hayesjf@mail.nih.gov)) or the NCI Program Director assigned to your P30 Cancer Center Support Grant.

Questions regarding fiscal and administrative matters should be addressed to the Grants Specialist for your Cancer Center, NCI Office of Grants Administration.